3SBio Inc. | Cash Flow

Fiscal year is January-December. All values HKD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
263
453
725
993
1,271
1,771
Depreciation, Depletion & Amortization
51
42
96
192
285
373
Other Funds
126
192
-
-
44
498
Funds from Operations
392
460
644
1,038
1,393
1,647
Changes in Working Capital
90
33
73
3
287
288
Net Operating Cash Flow
302
492
570
1,041
1,106
1,359
Capital Expenditures
50
33
120
545
299
Sale of Fixed Assets & Businesses
-
-
29
118
15
Purchase/Sale of Investments
381
127
2,298
398
241
Net Investing Cash Flow
580
406
4,048
5,142
757
Cash Dividends Paid - Total
618
829
-
-
-
Issuance/Reduction of Debt, Net
-
742
348
3,292
1,715
Net Financing Cash Flow
742
279
4,529
3,292
1,671
Net Change in Cash
136
202
1,195
756
1,987
Free Cash Flow
252
467
495
905
946
Deferred Taxes & Investment Tax Credit
2
-
-
-
-
-
Net Assets from Acquisitions
-
502
1,030
4,835
-
Other Sources
546
3
-
610
118
Change in Capital Stock
3
-
4,877
-
-
Exchange Rate Effect
3
10
144
52
32
Other Uses
298
2
628
91
350

About 3SBio

View Profile
Address
Shenyang Economy & Tech Development
Shenyang Liaoning 110027
China
Employees -
Website http://www.3sbio.com
Updated 07/08/2019
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products. It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company was founded by Jing Lou and Dan Lou in 1993 and is headquartered in Shenyang, China.